Immix Biopharma (NASDAQ:IMMX) Research Coverage Started at HC Wainwright

HC Wainwright initiated coverage on shares of Immix Biopharma (NASDAQ:IMMX) in a report published on Monday, MarketBeat reports. The firm issued a buy rating and a $7.00 price target on the stock. HC Wainwright also issued estimates for Immix Biopharma’s Q2 2024 earnings at ($0.21) EPS, Q3 2024 earnings at ($0.21) EPS, Q4 2024 earnings at ($0.19) EPS, FY2024 earnings at ($0.83) EPS, Q1 2025 earnings at ($0.17) EPS, Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.16) EPS, Q4 2025 earnings at ($0.15) EPS and FY2025 earnings at ($0.67) EPS.

Immix Biopharma Stock Up 25.0 %

Shares of NASDAQ:IMMX opened at $2.45 on Monday. The firm has a market cap of $64.71 million, a P/E ratio of -2.63 and a beta of 0.17. Immix Biopharma has a 12-month low of $1.55 and a 12-month high of $7.75. The business has a fifty day simple moving average of $2.16 and a 200 day simple moving average of $3.35.

Immix Biopharma (NASDAQ:IMMX) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.01. As a group, equities research analysts expect that Immix Biopharma will post -0.93 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Tocqueville Asset Management L.P. raised its stake in Immix Biopharma by 89.0% during the first quarter. Tocqueville Asset Management L.P. now owns 37,800 shares of the company’s stock worth $116,000 after buying an additional 17,800 shares during the last quarter. Tritonpoint Wealth LLC bought a new position in shares of Immix Biopharma in the 1st quarter worth about $75,000. Jump Financial LLC acquired a new position in shares of Immix Biopharma in the 4th quarter valued at about $128,000. Private Advisor Group LLC bought a new stake in shares of Immix Biopharma during the 4th quarter valued at about $690,000. Finally, OLD National Bancorp IN acquired a new stake in Immix Biopharma during the fourth quarter worth approximately $69,000. Institutional investors and hedge funds own 11.26% of the company’s stock.

About Immix Biopharma

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.